AtaiBeckley (ATAI) Convertible Debt (2020 - 2022)

AtaiBeckley's (ATAI) quarterly Convertible Debt came in at $380000.0 in Q3 2022, down 52.5% year-on-year from $800000.0 in Q3 2021, and down 38.61% quarter-over-quarter from $619000.0 in Q2 2022.

AtaiBeckley (ATAI) Convertible Debt (2020 - 2022) Analysis & Trends

AtaiBeckley has disclosed Convertible Debt across 3 years of filings, most recently posting $380000.0 for Q3 2022.

  • Convertible Debt for Q3 2022 came in at $380000.0, down 52.5% year-over-year; the trailing twelve-month figure through Sep 2022 was $380000.0 (down 52.5% YoY), and the FY2021 annual result was $743000.0, down 38.03% from the prior year.
  • Convertible Debt came in at $380000.0 for Q3 2022 at AtaiBeckley, down from $619000.0 in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $1.2 million in Q4 2020 to a low of $380000.0 in Q3 2022.
  • The 3-year median for Convertible Debt is $743000.0 (2021), against an average of $806000.0.
  • Across the five-year window, Convertible Debt sank 38.03% in 2021 and sank 52.5% in 2022, its largest moves.
  • AtaiBeckley's Convertible Debt stood at $1.2 million in 2020, then sank by 38.03% to $743000.0 in 2021, then sank by 48.86% to $380000.0 in 2022.
  • The last three Convertible Debt figures came in at $380000.0 (Q3 2022), $619000.0 (Q2 2022), and $725000.0 (Q1 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 AtaiBeckley 1.45 Bn 1.45 Bn -

Historic Data

Download Data
DateValue
Sep 30, 2022 380,000.00
Jun 30, 2022 619,000.00
Mar 31, 2022 725,000.00
Dec 31, 2021 743,000.00
Sep 30, 2021 800,000.00
Jun 30, 2021 1.18 Mn
Dec 31, 2020 1.20 Mn